The Covid-19 crisis has impelled the pharmaceutical companies to explore new strategies in a bid to address pandemic related clinical trial disruptions.

GlobalData conducted a survey to identify the key strategies that the companies are adopting to tackle clinical trial disruptions due to the coronavirus outbreak.

RPM emerges as key strategy to address Covid-19 related clinical trial disruptionsAddressing Clinical Trial Disruptions Related to the Covid-19 Outbreak

An analysis of the survey results shows that a signficant number of the companies have turned to remote patient monitoring (RPM) following new guidance from regulatory authorities that supported remote monitoring during the Covid-19 outbreak.​

Approximately 17% of the respondents stated that they were switching to RPM, which involves monitoring clinical trial patients over phone, email or patient portal.

Another 15% were planning to move to decentralised/ virtual trials for future programmes, while 14% are exploring remote site initiation visits for critical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, 13% of the companies asked their research staff to work remotely, while 11% were adopting direct-to-patient (DTP) drug delivery.

A total of 9% of the respondents halted screening or enrolment for all clinical trials and another 7% stopped initiating any new trial.

The survey also found that 7% of the companies are prioritising enrolment for certain clinical trials and the remaining 7% were pursuing remote safety lab collections.

The analysis is based on responses received from the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.